| An Open-label Study of GC012F in Rheumatoid Arthritis. (NCT07315503) | Institute of Hematology & Blood Diseases Hospital, China | 2027-12-01 |
| A Randomized Phase II Selection Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia (NCT07754799) | Institute of Hematology & Blood Diseases Hospital, China | 2026-09-30 |
| Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML. (NCT07757672) | Institute of Hematology & Blood Diseases Hospital, China | 2026-09-01 |
| Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia (NCT07188740) | Institute of Hematology & Blood Diseases Hospital, China | 2026-08-30 |
| A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia (NCT07692529) | Institute of Hematology & Blood Diseases Hospital, China | 2026-08-30 |
| Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse (NCT07686965) | Institute of Hematology & Blood Diseases Hospital, China | 2026-08-10 |
| A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL (NCT07723911) | Institute of Hematology & Blood Diseases Hospital, China | 2026-08-09 |
| Autologous Hematopoietic Stem Cell Transplantation for Neurological Damage Associated With Hereditary Homocysteine Remethylation Disorders (NCT07757685) | Institute of Hematology & Blood Diseases Hospital, China | 2026-08-01 |
| Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification (NCT07687004) | Institute of Hematology & Blood Diseases Hospital, China | 2026-08-01 |
| SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL) (NCT07725705) | Institute of Hematology & Blood Diseases Hospital, China | 2026-08-01 |
| CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment (NCT07585760) | Institute of Hematology & Blood Diseases Hospital, China | 2026-07-25 |
| BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004) (NCT07751471) | Institute of Hematology & Blood Diseases Hospital, China | 2026-07-20 |
| Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission (NCT07644481) | Institute of Hematology & Blood Diseases Hospital, China | 2026-07-20 |
| A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma (NCT07726160) | Institute of Hematology & Blood Diseases Hospital, China | 2026-07-20 |
| Plasma ctDNA Monitoring in Pediatric Acute Leukemia (NCT07751588) | Institute of Hematology & Blood Diseases Hospital, China | 2026-07-11 |
| Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP (NCT07687134) | Institute of Hematology & Blood Diseases Hospital, China | 2026-07-10 |
| META 10-19 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia (NCT07689604) | Institute of Hematology & Blood Diseases Hospital, China | 2026-07-08 |
| MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma (NCT07409454) | Institute of Hematology & Blood Diseases Hospital, China | 2026-07-07 |
| Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases (NCT07490275) | Institute of Hematology & Blood Diseases Hospital, China | 2026-07-01 |
| A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma (NCT07678307) | Institute of Hematology & Blood Diseases Hospital, China | 2026-06-30 |
| Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia (NCT07714512) | Institute of Hematology & Blood Diseases Hospital, China | 2026-06-30 |
| Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage (NCT06991920) | Institute of Hematology & Blood Diseases Hospital, China | 2026-06-30 |
| CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia (NCT07652905) | Institute of Hematology & Blood Diseases Hospital, China | 2026-06-20 |
| IASO206 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia (NCT07585071) | Institute of Hematology & Blood Diseases Hospital, China | 2026-06-15 |
| Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial (NCT07643103) | Institute of Hematology & Blood Diseases Hospital, China | 2026-06-12 |
| CM336-SOC for Dynamically High-Risk Multiple Myeloma Study (NCT07648459) | Institute of Hematology & Blood Diseases Hospital, China | 2026-06-01 |
| daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT (NCT07588945) | Institute of Hematology & Blood Diseases Hospital, China | 2026-06-01 |
| BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM (NCT07407010) | Institute of Hematology & Blood Diseases Hospital, China | 2026-06-01 |
| rhTPO Dose Escalation vs Eltrombopag Switch in ITP (NCT07476846) | Institute of Hematology & Blood Diseases Hospital, China | 2026-06-01 |
| ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL (NCT07454226) | Institute of Hematology & Blood Diseases Hospital, China | 2026-05-30 |
| Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML (NCT07490288) | Institute of Hematology & Blood Diseases Hospital, China | 2026-05-08 |
| Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma (NCT07539688) | Institute of Hematology & Blood Diseases Hospital, China | 2026-05-01 |
| VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (NCT07407140) | Institute of Hematology & Blood Diseases Hospital, China | 2026-04-30 |
| Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML (NCT07539818) | Institute of Hematology & Blood Diseases Hospital, China | 2026-04-29 |
| Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies (NCT07493174) | Institute of Hematology & Blood Diseases Hospital, China | 2026-04-15 |
| A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma. (NCT07539233) | Institute of Hematology & Blood Diseases Hospital, China | 2026-04-15 |
| A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide (NCT07585747) | Institute of Hematology & Blood Diseases Hospital, China | 2026-04-15 |
| The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignance Patients With Extramedullary Infiltrating (NCT07456189) | Institute of Hematology & Blood Diseases Hospital, China | 2026-04-14 |
| Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma (NCT07555470) | Institute of Hematology & Blood Diseases Hospital, China | 2026-04-10 |
| Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL (NCT07493161) | Institute of Hematology & Blood Diseases Hospital, China | 2026-04-10 |
| Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NCT07495631) | Institute of Hematology & Blood Diseases Hospital, China | 2026-04-08 |
| Exploratory Clinical Study on the Safety and Efficacy of CD19X CAR-T Cell Injection in the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (NCT07447726) | Institute of Hematology & Blood Diseases Hospital, China | 2026-04-05 |
| Establishment of Biomarker Panel For Forecasting Chronic Graft-Versus-Host Disease (cGVHD) After Allo-HSCT (NCT07539220) | Institute of Hematology & Blood Diseases Hospital, China | 2026-04-01 |
| Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors (NCT07539610) | Institute of Hematology & Blood Diseases Hospital, China | 2026-04-01 |
| A Real World Study of Polyene Phosphatidylcholine Injection for the Prevention and Treatment of DILI in Patients With Malignant Hematological Diseases (NCT07476885) | Institute of Hematology & Blood Diseases Hospital, China | 2026-03-31 |
| Study on the Pharmacokinetic Characteristics of Liposomal Amphotericin B in Patients With Invasive Fungal Infections Undergoing Plasma Exchange Therapy (NCT07532850) | Institute of Hematology & Blood Diseases Hospital, China | 2026-03-30 |
| Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma (NCT07441954) | Institute of Hematology & Blood Diseases Hospital, China | 2026-03-20 |
| Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD). (NCT07476872) | Institute of Hematology & Blood Diseases Hospital, China | 2026-03-16 |
| Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis (NCT07471503) | Institute of Hematology & Blood Diseases Hospital, China | 2026-03-16 |
| Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL (NCT07476027) | Institute of Hematology & Blood Diseases Hospital, China | 2026-03-15 |
| Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL (NCT07443488) | Institute of Hematology & Blood Diseases Hospital, China | 2026-03-14 |
| Reducing Post-Letermovir CMV Infection: Efficacy of an Immune-Reconstitution-Based Scoring System to Guide Prophylaxis Duration (NCT07443501) | Institute of Hematology & Blood Diseases Hospital, China | 2026-03-14 |
| The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT (NCT07450313) | Institute of Hematology & Blood Diseases Hospital, China | 2026-03-14 |
| A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia (NCT07441980) | Institute of Hematology & Blood Diseases Hospital, China | 2026-03-02 |
| Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) (NCT07362199) | Institute of Hematology & Blood Diseases Hospital, China | 2026-03-01 |
| PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） (NCT07406139) | Institute of Hematology & Blood Diseases Hospital, China | 2026-03-01 |
| Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) (NCT07362238) | Institute of Hematology & Blood Diseases Hospital, China | 2026-03-01 |
| Safety and Efficacy of KL003 Cell Injection in Severe Sickle Cell Disease (NCT07436767) | Institute of Hematology & Blood Diseases Hospital, China | 2026-03-01 |
| Early Clinical Study on the Use of Donor-derived EBV-specific T Cells for the Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation (NCT07476014) | Institute of Hematology & Blood Diseases Hospital, China | 2026-02-28 |
| Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia (NCT07471516) | Institute of Hematology & Blood Diseases Hospital, China | 2026-02-25 |
| Adverse Effects of ATG/ALG Therapy in Aplastic Anemia (NCT07461116) | Institute of Hematology & Blood Diseases Hospital, China | 2026-02-23 |
| The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation (NCT07441967) | Institute of Hematology & Blood Diseases Hospital, China | 2026-02-20 |
| Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry (NCT06992076) | Institute of Hematology & Blood Diseases Hospital, China | 2026-02-15 |
| IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma (NCT07185490) | Institute of Hematology & Blood Diseases Hospital, China | 2026-02-15 |
| A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplantation (NCT07381114) | Institute of Hematology & Blood Diseases Hospital, China | 2026-02-14 |
| SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma (NCT07234721) | Institute of Hematology & Blood Diseases Hospital, China | 2026-02-01 |
| A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases (NCT07212322) | Institute of Hematology & Blood Diseases Hospital, China | 2026-01-30 |
| Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) (NCT07234019) | Institute of Hematology & Blood Diseases Hospital, China | 2026-01-28 |
| Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) (NCT07297563) | Institute of Hematology & Blood Diseases Hospital, China | 2026-01-20 |
| JY509 Universal NK Cell Injection for the Treatment of Relapsed/Refractory Pediatric B-ALL (NCT07406178) | Institute of Hematology & Blood Diseases Hospital, China | 2026-01-20 |
| IASO206 in Patients With Relapsed/Refractory Multiple Myeloma (NCT07322159) | Institute of Hematology & Blood Diseases Hospital, China | 2026-01-15 |
| Zuberitamab for EBV Infection Post-Allo-HSCT (NCT07261215) | Institute of Hematology & Blood Diseases Hospital, China | 2026-01-14 |
| HID-HSCT Versus IST as First-line Treatment for SAA (NCT07338422) | Institute of Hematology & Blood Diseases Hospital, China | 2026-01-14 |
| A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001） (NCT07399444) | Institute of Hematology & Blood Diseases Hospital, China | 2026-01-10 |
| Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL (NCT07441993) | Institute of Hematology & Blood Diseases Hospital, China | 2026-01-05 |
| CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases (NCT07315087) | Institute of Hematology & Blood Diseases Hospital, China | 2026-01-01 |
| Perianal MBL-CRE Colonization and Infection in Allogeneic Hematopoietic Stem Cell Transplant Patients (NCT07324291) | Institute of Hematology & Blood Diseases Hospital, China | 2026-01-01 |
| A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia (NCT07259122) | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-30 |
| Unrelated Umbilical Cord Blood Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) (NCT07539662) | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-29 |
| Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma (NCT07299149) | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-25 |
| Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma (NCT07261163) | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-20 |
| A Cohort Study on the Association Between the ANS Function and Acute GvHD (NCT07374874) | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-18 |
| Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia (NCT07297550) | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-15 |
| Modified Conditioning Regimen for CML-BP (NCT07259161) | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-15 |
| Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy (NCT06770257) | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-10 |
| The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia (NCT07287228) | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-10 |
| Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy (NCT06570915) | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-01 |
| Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia (NCT07278908) | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-01 |
| Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL (NCT07278882) | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-01 |
| A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms (NCT07234045) | Institute of Hematology & Blood Diseases Hospital, China | 2025-11-30 |
| Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma (NCT07259070) | Institute of Hematology & Blood Diseases Hospital, China | 2025-11-29 |
| National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Primary Immune Thrombocytopenia (ITP) Patients (NCT07268898) | Institute of Hematology & Blood Diseases Hospital, China | 2025-11-25 |
| A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms (NCT07200479) | Institute of Hematology & Blood Diseases Hospital, China | 2025-10-30 |
| Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation (NCT07297576) | Institute of Hematology & Blood Diseases Hospital, China | 2025-10-22 |
| Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML (NCT06611839) | Institute of Hematology & Blood Diseases Hospital, China | 2025-10-17 |
| Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS (NCT07578675) | Institute of Hematology & Blood Diseases Hospital, China | 2025-10-11 |
| Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy (NCT07212335) | Institute of Hematology & Blood Diseases Hospital, China | 2025-10-01 |
| A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis (NCT07357038) | Institute of Hematology & Blood Diseases Hospital, China | 2025-09-30 |
| CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia (NCT07201727) | Institute of Hematology & Blood Diseases Hospital, China | 2025-09-30 |
| A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infection (NCT07141095) | Institute of Hematology & Blood Diseases Hospital, China | 2025-09-25 |